Of note, the association of a PARP inhibitor (niraparib) and anti PDL1 durvalumab is currently under investigation in SCLC-transformed EGFR-mutated NSCLC (NCT04538378). The gene discussed is EGFR; the disease is small cell lung carcinoma.